Comment by
BottomBroker on Jun 22, 2021 12:26pm
Finally, a story about Biogen that actually mentions PMN. This is big IMO. And pretty sure this isn't paid content, correct?
Comment by
retiredcop on Jun 22, 2021 12:41pm
Sorry to disappoint you .. Zachs is on our payroll for a few years now..
Comment by
DavidKingCanada on Jun 22, 2021 12:46pm
Payroll or not, any mention of PMN along side Biogen is in my opinion great news to look forward to. With most Small Cap Companies, this is the kind of publicity we need. Especially when one of them is Biogen and the other PMN.to ARFXF
Comment by
BottomBroker on Jun 22, 2021 12:56pm
Okay, so somewhere between paid content written by PMN and an independent, legitimate news story. I'm choosing to believe that's progress! Ha.
Comment by
M101 on Jun 22, 2021 5:09pm
It doesn't sound like Goldstein or his apprentice so maybe someone else approves ad copy now.
Comment by
Gbathat on Jun 22, 2021 7:24pm
Great shoutout to PMN in this article! Awesome!!!! I really like the analysis in the article too... offers a broad perspective of the aptly labeled saga. PMN mentioned next to Eli Lilly.... so you're telling me there's a chance! :D :D :-)
Comment by
TopBroker on Jun 22, 2021 8:33pm
With the amyloid theory being regenerated you would think a joint venture would be inevitable, but with an inept board and Gene who has never done a deal in his life, this may be impossible. What a useless board of Directors.
Comment by
DavidKingCanada on Jun 22, 2021 11:24pm
Indeed excellent News for PMN.to ARFXF! Imagine buying now and Biogen actually using PMN310. The SP will rise well above $1.00-$3.00. This is a Buy at the current SP and is a Long Term Investment (3-5 Years Exit).